138 related articles for article (PubMed ID: 31828320)
1. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
Costagliola D; Potard V; Lang S; de Castro N; Cotte L; Duval X; Duvivier C; Grabar S; Mary-Krause M; Partisani M; Ronot-Bregigeon S; Simon A; Tattevin P; Weiss L; Zucman D; Katlama C; Raffi F; Boccara F
J Infect Dis; 2020 Feb; 221(4):516-522. PubMed ID: 31828320
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
Ryom L; Lundgren JD; El-Sadr W; Reiss P; Kirk O; Law M; Phillips A; Weber R; Fontas E; d' Arminio Monforte A; De Wit S; Dabis F; Hatleberg CI; Sabin C; Mocroft A;
Lancet HIV; 2018 Jun; 5(6):e291-e300. PubMed ID: 29731407
[TBL] [Abstract][Full Text] [Related]
3. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
[TBL] [Abstract][Full Text] [Related]
4. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
J Med Econ; 2016; 19(4):386-96. PubMed ID: 26640980
[TBL] [Abstract][Full Text] [Related]
5. Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
Jose S; Nelson M; Phillips A; Chadwick D; Trevelion R; Jones R; Williams DI; Hamzah L; Sabin CA; Post FA;
AIDS; 2017 Feb; 31(4):485-492. PubMed ID: 28121667
[TBL] [Abstract][Full Text] [Related]
6. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Costagliola D;
Arch Intern Med; 2010 Jul; 170(14):1228-38. PubMed ID: 20660842
[TBL] [Abstract][Full Text] [Related]
7. Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord
Antivir Ther; 2016; 21(4):353-8. PubMed ID: 26561496
[TBL] [Abstract][Full Text] [Related]
8. Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study.
Rosenblatt L; Farr AM; Nkhoma ET; Nelson JK; Ritchings C; Johnston SS
BMC Infect Dis; 2016 Sep; 16():492. PubMed ID: 27643691
[TBL] [Abstract][Full Text] [Related]
9. Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4).
Guiguet M; Mary-Krause M; Ename B; Costagliola D; Grabar S
Pharmacoepidemiol Drug Saf; 2008 May; 17(5):468-74. PubMed ID: 18324608
[TBL] [Abstract][Full Text] [Related]
10. Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
Li M; Chan WW; Zucker SD
J Am Heart Assoc; 2020 Oct; 9(19):e016310. PubMed ID: 32930032
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.
LaFleur J; Bress AP; Rosenblatt L; Crook J; Sax PE; Myers J; Ritchings C
AIDS; 2017 Sep; 31(15):2095-2106. PubMed ID: 28692532
[TBL] [Abstract][Full Text] [Related]
12. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
[TBL] [Abstract][Full Text] [Related]
13. Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV.
Adrian S; Miao H; Feng H; Scherzinger A; Nardini G; Beghetto B; Roncaglia E; Ligabue G; Milic J; Guaraldi G; Lake JE; Erlandson KM
HIV Res Clin Pract; 2020 Aug; 21(4):91-98. PubMed ID: 32878571
[TBL] [Abstract][Full Text] [Related]
14. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
Brogan AJ; Davis AE; Goodwin B
PLoS One; 2018; 13(8):e0203293. PubMed ID: 30161205
[TBL] [Abstract][Full Text] [Related]
15. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort.
d'Arminio Monforte A; Lorenzini P; Cozzi-Lepri A; Mussini C; Castagna A; Baldelli F; Puoti M; Vichi F; Maddaloni A; Lo Caputo S; Gianotti N; Antinori A;
HIV Clin Trials; 2018 Apr; 19(2):52-60. PubMed ID: 29493419
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.
Dentone C; Di Biagio A; Cozzi Lepri A; Fenoglio D; Filaci G; Lichtner M; Carrara S; Giacometti A; Sighinolfi L; Marchetti G; Antinori A; D'arminio Monforte A;
HIV Clin Trials; 2018 Aug; 19(4):158-162. PubMed ID: 30422095
[TBL] [Abstract][Full Text] [Related]
17. Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case-Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4).
Costagliola D; Potard V; Lang S; Abgrall S; Duvivier C; Fischer H; Joly V; Lacombe JM; Valantin MA; Mary-Krause M; Rozenberg S
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):214-223. PubMed ID: 30422911
[TBL] [Abstract][Full Text] [Related]
18. Higher plasma drug levels in elderly people living with HIV treated with darunavir.
Tyrberg E; Edén A; Eriksen J; Nilsson S; Treutiger CJ; Thalme A; Mellgren Å; Gisslén M; Andersson LM
PLoS One; 2021; 16(2):e0246171. PubMed ID: 33539440
[TBL] [Abstract][Full Text] [Related]
19. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study.
Antinori A; Rusconi S; Gianotti N; Bini T; Mancusi D; Termini R
Drug Des Devel Ther; 2019; 13():1667-1685. PubMed ID: 31190745
[No Abstract] [Full Text] [Related]
[Next] [New Search]
